Genelux appoints Jason Litten as CMO after Paul Scigalla resigns

GENELUX Corp

Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.
Jason Litten, M.D., appointed CMO effective January 2, 2026; previously CMO at Chimeric Therapeutics.
Dr. Litten receives base salary of $475,000/year, 40% target bonus, and option to purchase 275,000 shares vesting over 4 years.
Severance: 6 months salary (non-CIC) or 12 months (CIC) plus COBRA coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.